The abstract is read at the publisher; the summary is JClub's.
Image-based consensus molecular subtyping (imCMS) of stage II/III colorectal cancer in the SCOT trial is strongly prognostic independent of clinicopathologic factors, dMMR, and CD8 IE -FoxP3 IS.
- Why it matters: Risk stratification in localized CRC is inadequate, and transcriptome-based CMS is difficult to implement, creating a need for a practical method that still predicts recurrence and survival.
- What they did: A novel imCMS classifier was applied to routine pathology images from 2,816 informative SCOT trial cases, then associations and prognostic/predictive effects were tested using univariable and multivariable Cox regression.
- The result: imCMS1 (24%), imCMS2 (35%), imCMS3 (15%), imCMS4 (23%), and mixed (3%) subtypes showed distinct biology and recurrence risk; imCMS did not predict differential chemotherapy duration or regimen benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.